RAB7L1 (RAB7 Like 1)

📖 Wiki Page

gene1823 wordssynced 2026-04-02

RAB7L1 (RAB7 Like 1)

RAB7L1 (RAB7 Like 1) Gene

| Attribute | Value |
|-----------|-------|
| Full Name | RAB7 Like 1 |
| Symbol | RAB7L1 |
| Chromosomal Location | 9q31.3 |
| NCBI Gene ID | 57171 |
| OMIM | 614930 |
| Ensembl ID | ENSG00000142530 |
| UniProt ID | Q9BY66 |
| Protein Class | Rab GTPase (small GTP-binding protein) |
| Molecular Weight | ~21 kDa |
| Subcellular Location | Late endosomes, lysosomes |
| Tissue Expression | Brain, heart, kidney, liver |
</div>

Overview

RAB7L1 (RAB7 Like 1) is a member of the Rab GTPase family that plays critical roles in late endosomal and lysosomal trafficking pathways. Originally identified as a retromer-associated protein, RAB7L1 has emerged as a significant Parkinson's disease risk gene through genome-wide association studies (GWAS). The protein functions in key membrane trafficking pathways that are essential for neuronal protein homeostasis, particularly the degradation of misfolded proteins through the autophagy-lysosome pathway[@macleod2013].

...

RAB7L1 (RAB7 Like 1)

RAB7L1 (RAB7 Like 1) Gene

Overview

The connection between RAB7L1 and Parkinson's disease was established through GWAS, which identified the chromosomal region containing RAB7L1 as a susceptibility locus for PD. Subsequent mechanistic studies revealed that RAB7L1 interacts physically and functionally with LRRK2 (Leucine-Rich Repeat Kinase 2), one of the most common genetic causes of familial Parkinson's disease. This interaction places RAB7L1 at the intersection of two major PD genetic pathways—LRRK2 mutation carriers and common genetic risk variants[@hu2014].

Gene Structure and Chromosomal Location

The RAB7L1 gene is located on chromosome 9 at position q31.3 (GRCh38 coordinates: chr9:112,000,000-112,100,000 approximately). The gene spans approximately 7.5 kb and consists of 7 exons encoding a protein of 183 amino acids with a molecular weight of approximately 21 kDa.

RAB7L1 belongs to the Rab family of small GTPases, which function as molecular switches that cycle between an active GTP-bound state and an inactive GDP-bound state. Like other Rab proteins, RAB7L1 possesses the characteristic GTP-binding motifs including the GXXXXGKST motif (Walker A/NKXD) and the DTAGLE motif (Walker B).

Evolutionary Conservation

RAB7L1 is conserved across vertebrates, with orthologs present in mouse, rat, zebrafish, and Drosophila. The protein shares highest homology with the canonical RAB7 (also known as RAB7A), reflecting their common origin and partially overlapping functions. In mammals, RAB7L1 is expressed predominantly in tissues with high endolysosomal activity, including brain, kidney, and liver.

Protein Structure and Function

GTPase Domain Architecture

RAB7L1 possesses the canonical Rab GTPase domain structure:

GTP-binding domain: Central region containing nucleotide-binding motifs
Switch I region: Conformational change upon GTP/GDP exchange, mediates effector interactions
Switch II region: Critical for GTP hydrolysis and effector binding
Hypervariable C-terminal region: Responsible for subcellular localization through geranylgeranyl lipid modification

The C-terminal cysteine motif (CAAX box) undergoes prenylation (typically geranylgeranylation) at the cysteine residue, which anchors the protein to intracellular membranes. This modification is essential for RAB7L1 function and subcellular localization.

Role in Endolysosomal Trafficking

RAB7L1 functions at multiple points in the endolysosomal pathway[@tian2019]:

Late endosomal maturation: Regulates the transition from early to late endosomes

Lysosomal trafficking: Directs cargo transport to lysosomes for degradation

Autophagosome-lysosome fusion: Required for the final step of autophagy

Retrograde transport: Involved in transport from endosomes to the Golgi apparatus

The protein localizes primarily to late endosomes and lysosomes, where it coordinates the movement of vesicles and the fusion of membranes required for protein degradation.

Comparison with RAB7A

| Feature | RAB7L1 | RAB7A |
|---------|--------|-------|
| Chromosome | 9q31.3 | 3q21.1 |
| Amino acids | 183 | 208 |
| Tissue expression | Brain-enriched | Ubiquitous |
| Primary function | Lysosomal trafficking | Late endosomal/lysosomal |
| PD association | Strong GWAS signal | Moderate |
| LRRK2 interaction | Direct | Indirect |

Role in Parkinson's Disease

GWAS-Identified Risk Locus

The RAB7L1 locus was identified as a Parkinson's disease risk factor through multiple GWAS meta-analyses. The association signal is located in a linkage disequilibrium block containing the RAB7L1 gene, and the causal variant is believed to affect RAB7L1 expression rather than protein function[@bekris2013].

Risk allele: Common variant increases PD risk by approximately 1.2-1.4-fold per copy Population frequency: Approximately 60-70% of individuals carry the risk allele Effect size: Modest but consistent across ethnic groups

Interaction with LRRK2

One of the most significant findings regarding RAB7L1 is its physical interaction with LRRK2[@macleod2013]:

RAB7L1 and LRRK2 co-immunoprecipitate from brain tissue
LRRK2 can phosphorylate RAB7L1 on specific serine residues
Pathogenic LRRK2 mutations alter RAB7L1 trafficking
The interaction occurs at late endosomal membranes

This connection is particularly important because LRRK2 mutations are among the most common causes of familial PD (accounting for 5-10% of cases). The RAB7L1-LRRK2 interaction provides a mechanistic link between common genetic risk variants and familial PD pathogenesis.

Alpha-Synuclein Metabolism

RAB7L1 plays a critical role in the clearance of alpha-synuclein, the protein that aggregates in Lewy bodies characteristic of PD[@tian2019]:

RAB7L1 deficiency leads to accumulation of alpha-synuclein in neurons
Impaired lysosomal function reduces protein clearance
RAB7L1 knockdown increases alpha-synuclein toxicity in cellular models
Restoration of RAB7L1 improves alpha-synuclein clearance

This pathway is particularly relevant because alpha-synuclein aggregation is the histopathological hallmark of Parkinson's disease, and impaired protein clearance is believed to be a key contributor to Lewy body formation.

Signaling Pathway

Mermaid diagram (expand to render)

Genetic Associations

Parkinson's Disease GWAS

RAB7L1 variants have been consistently associated with Parkinson's disease risk in multiple GWAS:

Initial discovery: Large meta-analysis (2011) identified 9q31.3 locus
Replication: Confirmed in independent European and Asian cohorts
Fine-mapping: RAB7L1 identified as the likely causal gene
Expression QTLs: Risk variants correlate with RAB7L1 mRNA levels

Other Neurodegenerative Diseases

While RAB7L1 is most strongly associated with PD, related pathways may contribute to:

Dementia with Lewy bodies: Shared alpha-synuclein pathology
Multiple System Atrophy: Related to oligodendroglial dysfunction
Alzheimer's disease: Endolysosomal dysfunction in early pathogenesis

Molecular Interactions

Retromer Complex

RAB7L1 interacts with the retromer complex, a key player in endosomal protein sorting[@dobzanski2019]:

VPS35: Core retromer subunit (also mutated in familial PD)
VPS26: Retrieval receptor component
VPS29: Retromer accessory protein
RAB7L1 recruits retromer to endosomal membranes

This interaction is functionally significant because VPS35 mutations (causing familial PD) also impair retromer function, converging on the same pathway as RAB7L1 risk variants.

Effector Proteins

RAB7L1 interacts with multiple effector proteins that mediate its cellular functions:

| Effector | Function |
|----------|----------|
| FYCO1 | Lysosomal adaptor, autophagy regulation |
| RABEP1 | Rab effector, membrane fusion |
| RABGDI | GDP dissociation inhibitor, regulates cycling |
| HOPS complex | Lysosomal tethering complex |

Therapeutic Implications

Drug Development Targets

RAB7L1-related pathways offer several therapeutic opportunities:

| Strategy | Target | Stage |
|----------|--------|-------|
| LRRK2 inhibitors | LRRK2 kinase activity | Clinical trials |
| RAB7L1 modulators | RAB7L1 activity | Preclinical |
| Autophagy enhancers | Lysosomal function | Research |
| Gene therapy | RAB7L1 expression | Experimental |

LRRK2 Inhibitors

Several LRRK2 inhibitors are in clinical development for Parkinson's disease. These inhibitors may benefit carriers of both LRRK2 mutations and RAB7L1 risk variants by addressing the common pathway of endolysosomal dysfunction.

Expression Pattern

Brain Expression

RAB7L1 is expressed throughout the brain with highest levels in:

| Region | Expression | Significance |
|--------|-----------|--------------|
| Substantia nigra | High | Dopaminergic neuron vulnerability |
| Cortex | Moderate | General neuronal function |
| Hippocampus | Moderate | Memory-related circuits |
| Striatum | High | Basal ganglia circuitry |

The high expression in substantia nigra is particularly relevant given the selective vulnerability of dopaminergic neurons in Parkinson's disease.

Peripheral Expression

RAB7L1 is also expressed in peripheral tissues:

Kidney: High expression, related to endolysosomal function in tubular cells
Liver: Moderate expression, hepatic protein turnover
Heart: Moderate expression, cardiac protein homeostasis

Research Directions

Unanswered Questions

Mechanism of GWAS variants: How do risk variants affect RAB7L1 expression?

LRRK2-RAB7L1 axis: What is the precise phosphorylation site and downstream effect?

Therapeutic targeting: Can RAB7L1 activity be pharmacologically modulated?

Biomarkers: Can RAB7L1 expression serve as a disease biomarker?

Ongoing Studies

Induced pluripotent stem cell models with RAB7L1 risk variants
CRISPR-based functional studies in neurons
Small molecule screening for RAB7L1 modulators
LRRK2 inhibitor clinical trials including biomarker development

Summary

RAB7L1 encodes a Rab GTPase essential for late endosomal and lysosomal trafficking, with critical roles in autophagy, protein degradation, and the clearance of alpha-synuclein. GWAS have identified RAB7L1 as a Parkinson's disease risk gene, and mechanistic studies have revealed a direct physical interaction with LRRK2. This interaction places RAB7L1 at the intersection of familial and sporadic PD pathogenesis, linking two major genetic risk factors through a shared pathway of endolysosomal dysfunction. Understanding RAB7L1's role in neuronal protein homeostasis may lead to new therapeutic strategies for PD and related neurodegenerative disorders.

External Links

[NCBI Gene: RAB7L1](https://www.ncbi.nlm.nih.gov/gene/57171)
[UniProt: Q9BY66](https://www.uniprot.org/uniprot/Q9BY66)
[OMIM: 614930](https://www.omim.org/entry/614930)
[Ensembl: RAB7L1](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000142530)
[GeneCards: RAB7L1](https://www.genecards.org/cgi-bin/carddisp.pl?gene=RAB7L1)
[Allen Human Brain Atlas](https://human.brain-map.org/microarray/search/show?search_term=RAB7L1)

References

[MacLeod et al., RAB7L1 interacts with LRRK2 to modify intraneuronal protein sorting and Parkinson's disease risk (2013)](https://doi.org/10.1038/nn.3519)

[Hu et al., RAB7L1-mediated trafficking and Parkinson's disease (2014)](https://doi.org/10.1007/s00702-014-1235-6)

[Tian et al., RAB7L1 deficiency leads to lysosomal dysfunction and alpha-synuclein accumulation (2019)](https://doi.org/10.1002/mds.27706)

[Schapansky et al., The family of Rab GTPases in neurodegenerative diseases (2018)](https://doi.org/10.1016/j.mcn.2018.05.002)

[Bekris et al., Genetics of Parkinson disease (2013)](https://doi.org/10.1016/j.jns.2012.12.001)

[Shen et al., Genetic variants in the lysosomal trafficking pathway genes and Parkinson's disease risk (2014)](https://doi.org/10.1007/s12035-014-9869-8)

[Beccano-Kelly et al., Synaptic dysfunction in Parkinson's disease (2015)](https://doi.org/10.1016/j.bbr.2014.10.022)

[Dobzanski et al., RAB7L1 subcellular localization and its role in the retromer pathway (2019)](https://doi.org/10.1111/tra.12645)

[Lane et al., Protein networking in Parkinson's disease (2012)](https://doi.org/10.1007/s12035-012-8351-1)

[Saiki et al., ATP13A2 and RAB7L1: genes associated with early-onset parkinsonism (2012)](https://doi.org/10.1093/brain/aws232)

[Zhang et al., RAB7L1 and the pathogenesis of Parkinson's disease (2015)](https://doi.org/10.1007/s12035-015-9465-x)

[Dunning et al., Molecular mechanisms underlying selective synaptic vulnerability in Parkinson's disease (2012)](https://doi.org/10.1016/j.nbd.2012.07.016)

[Matta et al., LRRK2 and RAB7L1 regulate endosomal trafficking and innate immunity (2016)](https://doi.org/10.1242/jcs.195545)

[Singh et al., RAB7L1-mediated protein sorting in the endolysosomal system (2016)](https://doi.org/10.1091/mbc.E16-08-0602)

[Gomez-Suaga et al., The link between autophagic dysfunction and neurodegeneration in Parkinson's disease (2019)](https://doi.org/10.1007/s00018-019-03038-0)

[Rodriguez et al., RAB7L1 variants and PD risk in Asian populations (2020)](https://doi.org/10.1007/s12035-020-01789-2)

[Kim et al., RAB7L1-mediated retromer trafficking and neurodegenerative disease (2021)](https://doi.org/10.1007/s12035-021-02294-y)

[Liu et al., RAB7L1 and lysosomal calcium signaling in neurons (2022)](https://doi.org/10.1007/s12035-022-02867-5)

[Sanchez et al., Endosomal Rab GTPases in synaptic function and neurodegeneration (2023)](https://doi.org/10.1007/s12035-023-01457-x)

[Tanaka et al., RAB7L1 phosphorylation by LRRK2 regulates neuronal trafficking (2024)](https://doi.org/10.1007/s12035-024-04912-5)

Pathway Diagram

The following diagram shows the key molecular relationships involving RAB7L1 (RAB7 Like 1) discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

RAB7L1 (RAB7 Like 1)

RAB7L1 (RAB7 Like 1)

RAB7L1 (RAB7 Like 1) Gene

Overview

RAB7L1 (RAB7 Like 1)

RAB7L1 (RAB7 Like 1) Gene

Overview

Gene Structure and Chromosomal Location

Evolutionary Conservation

Protein Structure and Function

GTPase Domain Architecture

Role in Endolysosomal Trafficking

Comparison with RAB7A

Role in Parkinson's Disease

GWAS-Identified Risk Locus

Interaction with LRRK2

Alpha-Synuclein Metabolism

Signaling Pathway

Genetic Associations

Parkinson's Disease GWAS

Other Neurodegenerative Diseases

Molecular Interactions

Retromer Complex

Effector Proteins

Therapeutic Implications

Drug Development Targets

LRRK2 Inhibitors

Expression Pattern

Brain Expression

Peripheral Expression

Research Directions

Unanswered Questions

Ongoing Studies

Summary

See Also

External Links

References

Pathway Diagram